Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).


For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.


We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.


In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.


We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.


We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.


The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.


Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.


Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.


If you want more information or have any questions or comments relating to our privacy policy please email [email protected] in the first instance.

 Information  X 
Enter a valid email address

Xenova Group PLC (XEN)

  Print      Mail a friend

Tuesday 05 February, 2002

Xenova Group PLC

Research Update

Xenova Group PLC
5 February 2002

For Immediate Release

                                 Xenova Group plc

              Anti-Cancer Compound XR11576 Enters Clinical Trials

Slough, UK, 5 February 2002 - Xenova Group plc (NASDAQ: XNVA; London Stock
Exchange: XEN) today announced that patient dosing has begun at the University
Hospital of Rotterdam, Rotterdam Cancer Institute with XR11576 (MLN576), a novel
anti-cancer agent.

This open label, Phase I trial is being carried out at centres in the UK and the
Netherlands and comprises multiple ascending oral doses in patients with solid
tumours.  Patients will be monitored for safety, tolerability, pharmacokinetics
and anti-tumour activity.

XR11576 (MLN576) is one of a programme of compounds for the treatment of solid
tumours.  Along with compounds XR5944 (MLN944) and XR11612 (MLN612), XR11576
(MLN576) is the subject of a licence agreement with Millennium Pharmaceuticals
Inc, which was announced in December 2001 for the development and exclusive
North American commercialisation rights to this programme.  The compounds are
believed to be novel DNA targeting agents that affect the DNA replication
process through a mechanism of action which involves the dual inhibition of
topoisomerases I and II.  Xenova retains responsibility for performing
development activities associated with the programme, which will be funded by
Millennium commencing in 2003, to the end of Phase II clinical trials.

David Oxlade, Xenova's Chief Executive, said: 'XR11576 has shown considerable
promise in preclinical studies including good oral bioavailability.  These
compounds have a novel and exciting mechanism of action and have shown
considerable evidence of activity in in vivo xenograft models.  There remains a
clear need in the marketplace for new cytotoxics in order to improve the quality
of treatment and outcomes for a large number of cancer patients.'


Xenova Group plc                                              Financial Dynamics

David Oxlade, Chief Executive Officer                   David Yates/Fiona Noblet
Daniel Abrams, Finance Director                         Tel: +44(0) 207 831 3113
Hilary Reid Evans, Head of Corporate Communications
Tel: +44 (0) 1753 706600

Trout Group/BMC Communications
Press: Brad Miles (Ext 17) Lauren Tortorete (Ext 20)
Investors: Jonathan Fassberg (Ext 16) Lee Stern (Ext 22)
Tel: 001 212 477 9007

Notes to Editors

Xenova Group plc's product pipeline focuses principally on cancer and
immunotherapy.  Xenova currently has a broad pipeline of products in clinical
development.  The multi-drug resistance modulator tariquidar/XR9576, North
American rights for which were licensed to QLT Inc in August 2001, is expected
to enter Phase III clinical trials during the first half of 2002. Two
immunotherapeutic vaccines,TA-HPV and TA-CIN, are undergoing Phase II 
'Prime-Boost' clinical trials in combination for the treatment of ano-genital
dysplasia and a third vaccine, DISC-GMCSF, is being evaluated for the treatment
of malignant melanoma.  In non-cancer related therapy areas, TA-CD, a vaccine
for the treatment of cocaine addiction, is currently undergoing Phase II trials
and  a vaccine for the treatment of nicotine addiction, TA-NIC, is in Phase I
clinical trials.  DISC-PRO, a vaccine for the prevention of herpes, has
completed Phase I trials.  In addition, a product candidate for the prevention
of bovine herpes, DISC-BHV, was entered into development by Xenova's global
partner, Pfizer Animal Health, in January 2001.

The Group has a well-established track record in the identification, development
and partnering of innovative products and technologies and has partnerships with
major pharmaceutical companies including Lilly, Pfizer, Celltech, QLT and

For further information about Xenova and its products please visit the Xenova
website at

Disclaimer to take advantage of the 'Safe Harbor' provisions of the US Private
Securities Litigation Reform Act of 1995. This press release contains 
'forward-looking statements,' including statements about the discovery,
development and commercialisation of products. Various risks may cause Xenova's
actual results to differ materially from those expressed or implied by the
forward looking statements, including: adverse results in our drug discovery and
clinical development programs; failure to obtain patent protection for our
discoveries; commercial limitations imposed by patents owned or controlled by
third parties; our dependence upon strategic alliance partners to develop and
commercialise products and services; difficulties or delays in obtaining
regulatory approvals to market products and services resulting from our
development efforts; the requirement for substantial funding to conduct research
and development and to expand commercialisation activities; and product
initiatives by competitors.  For a further list and description of the risks and
uncertainties we face, see the reports we have filed with the Securities and
Exchange Commission.  We disclaim any intention or obligation to update or
revise any forward-looking statements, whether as a result of new information,
future events or otherwise.

                      This information is provided by RNS
            The company news service from the London Stock Exchange


a d v e r t i s e m e n t